According to AdaptHealth's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 27.9. At the end of 2022 the company had a P/E ratio of 40.0.
Year | P/E ratio | Change |
---|---|---|
2022 | 40.0 | 76.8% |
2021 | 22.6 | -225.42% |
2020 | -18.1 | -43.49% |
2019 | -32.0 | -121.7% |
2018 | 147 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() | < -1000 | -5,832.62% | ๐บ๐ธ USA |
![]() | 59.6 | 113.53% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.